electronRx to launch smartphone app for remote lung function monitoring
electronRx announced that it will launch purpleDx, a cardiopulmonary assessment app built to medical device standards, that enables chronic respiratory disease (CRD) patients to detect and monitor digital biomarkers of lung function at home, while providing clinicians with real-time data to customize treatment plans.
purpleDx is a smartphone app with accompanying clinical dashboard to support clinicians in detecting, monitoring, and treating pulmonary diseases, including asthma, chronic obstructive pulmonary disease, interstitial lung disease and pulmonary hypertension. It was developed in collaboration with several respiratory clinics and the company’s recent charity partner, the European pulmonary hypertension association (PHA Europe).
The scalable technology utilizes digital biomarkers generated from mobile device sensors that feed into high impact actionable clinical biomarkers to assess physiological cardiopulmonary metrics, such as heart rate, respiratory rate and tidal volume. Healthcare providers can access the physiological data in real time via the clinical dashboard, enabling them to monitor patients’ lung function remotely and adjust treatment plans accordingly to help optimize drug efficacy. Remote monitoring also ensures patients need only travel to the hospital when necessary, saving them time and energy as well as helping to streamline healthcare delivery.
These digital apps are built onto the iPhone and use the camera to capture and measure the blood flow around the face that is invisible to the human eye. A typical 30–60 second measurement captures millions of data points that can then be converted into digital biomarkers to capture a range of physiological measurements.
